CorFlow Presents at the PCR Innovators Day and New Data During EuroPCR 2019

EuroPCR is one of the leading interventional cardiology conferences in the world celebrating its 30th anniversary this year
(PresseBox) ( Baar, )
CorFlow Therapeutics AG ("CorFlow") today announced that the company will present the Controlled Flow Infusion (CoFI™) technology for diagnosis and treatment of microvascular obstruction in patients with myocardial infarction during the upcoming PCR Innovators Day, to be held in Paris, France. Also in Paris, at EuroPCR, the company will present new preclinical findings related to intra-coronary drug infusion and how coronary artery collateral resistance and flow can be measured directly using the CoFI™ technique in the context of myocardial infarction.

The presentation during the PCR Innovators Day will be made by Prof. Javier Escaned who is the Head of the Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). Prof. Escaned is a respected interventional cardiologist with a strong track record in coronary vascular physiology and treatment options for heart attack patients.

The other posters and presentations will be made by Dr. Robert S. Schwartz, Senior Consulting Cardiologist at the Minneapolis Heart Institute (Minneapolis, MN, USA) and co-Founder of CorFlow.

Dr. Schwartz commented on this years CorFlow presentations during EuroPCR: "We are excited that the CorFlow technologies continue to open up new insights into the coronary microcirculation. This will be reflected in our presentations during the EuroPCR conference. We also appreciate that Prof. Escaned with his deep understanding of coronary physiology and coronary treatment options will present his perspectives on the CoFI™ technology during the highly regarded PCR Innovators Day."

The company will present the CoFI™ technology during three different sessions:

Monday May 20th @ 08:35 during PCR Innovators Day, Theatre Havane / level 3, during the session "Sticky problems, new solutions"
"CorFlow Therapeutics – Controlled flow infusion: a single platform for intracoronary diagnosis and treatment of microvascular obstruction in patients with AMI" presented by Prof. Javier Escaned

Tuesday May 21st to Friday May 24th @ 09:00 - 18:00 in the POSTERLAB / level 3
"Intracoronary tirofiban delivered by controlled flow infusion: marked reduction of microvascular obstruction in a porcine STEMI model" presented by Dr. Robert S. Schwartz

"Absolute coronary collateral flow and resistance during STEMI using the controlled flow infusion method" presented by Dr. Robert S. Schwartz

Tuesday May 21st @ 12:24 in the POSTERLAB / level 3 during the moderated poster session "Unanswered questions in STEMI patients", facilitated by Dr. A. Erglis and Dr. G. Gargiulo
"Intracoronary tirofiban delivered by controlled flow infusion: marked reduction of microvascular obstruction in a porcine STEMI model" presented by Dr. Robert S. Schwartz

The first poster describes studies of selective intra-coronary tirofiban delivery to the heart muscle affected by the myocardial infarction using the CorFlow CoFI™ System, and how it reduces microvascular obstruction as measured by MRI in a preclinical occlusion-reperfusion model. Even if preclinical models never can be completely representative of a human heart attack, the findings document that using a controlled method of intra-coronary tirofiban infusion has a positive effect on microvascular obstruction in the established CorFlow preclinical microvascular obstruction model.

The second poster describes how collateral coronary flow and resistance can be directly measured using the CoFI™ methods. These parameters have never been measured previously and may open novel diagnostic and therapeutic strategies. Furthermore, this technique is important to make coronary resistance calculations substantially more reliable.

Overall, the data due to be presented this month at these two important scientific meetings will contribute to consolidate the CorFlow CoFI™ technology as a solution to a major unmet need in patients with STEMI, namely the need for a dedicated diagnostic and therapeutic platform to address microvascular obstruction and, eventually, improve clinical outcomes.  
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to